<DOC>
	<DOC>NCT02259309</DOC>
	<brief_summary>The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.</brief_summary>
	<brief_title>Immune Modulation by Misoprostol</brief_title>
	<detailed_description />
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Healthy women 1845 years of age Negative result of urine pregnancy test at screening and prior to each administration of study drug Normal, regularly occurring menses (being 2535 day cycles) Use of hormonal contraception (current or past 3 months) Use of nonsteroidal antiinflammatory drugs (NSAIDs) or aspirin within two weeks prior to enrollment or planned use of these medications during the study period Allergy to prostaglandins Previous cervical cancer Partial or complete cervical excision Previous hysterectomy Immunosuppression: either pharmacological or due to comorbidities Diabetes mellitus Autoimmune disease History of lymphoma or leukemia Sexually transmitted infection (by selfreport) over previous 1 year Bacterial Vaginosis or Candidiasis (current or past 3 months)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>misoprostol</keyword>
	<keyword>mucosal</keyword>
	<keyword>cervical</keyword>
	<keyword>immune</keyword>
	<keyword>buccal</keyword>
	<keyword>vaginal</keyword>
</DOC>